Literature DB >> 25118637

Tavaborole: first global approval.

Anthony Markham1.   

Abstract

Tavaborole is a novel, low-molecular weight oxaborole antifungal drug under development by Anacor Pharmaceuticals Inc. for the topical treatment of onychomycosis of the toenail. The drug has received its first global approval for this indication in the US. This article summarizes the milestones in the development of tavaborole leading to this first approval for onychomycosis of the toenails.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25118637     DOI： 10.1007/s40265-014-0276-7

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  4 in total

Review 1.  Current and emerging options in the treatment of onychomycosis.

Authors:  Boni Elewski; David Pariser; Phoebe Rich; Richard K Scher
Journal:  Semin Cutan Med Surg       Date:  2013-06

2.  Tavaborole for the treatment of onychomycosis.

Authors:  Boni E Elewski; Antonella Tosti
Journal:  Expert Opin Pharmacother       Date:  2014-05-26       Impact factor: 3.889

3.  An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.

Authors:  Fernando L Rock; Weimin Mao; Anya Yaremchuk; Mikhail Tukalo; Thibaut Crépin; Huchen Zhou; Yong-Kang Zhang; Vincent Hernandez; Tsutomu Akama; Stephen J Baker; Jacob J Plattner; Lucy Shapiro; Susan A Martinis; Stephen J Benkovic; Stephen Cusack; M R K Alley
Journal:  Science       Date:  2007-06-22       Impact factor: 47.728

4.  In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.

Authors:  Xiaoying Hui; Stephen J Baker; Ronald C Wester; Sherry Barbadillo; Anne K Cashmore; Virginia Sanders; Karin M Hold; Tsutomu Akama; Yong-Kang Zhang; Jacob J Plattner; Howard I Maibach
Journal:  J Pharm Sci       Date:  2007-10       Impact factor: 3.534
  4 in total
  10 in total

Review 1.  Network Meta-Analysis of Onychomycosis Treatments.

Authors:  Aditya K Gupta; Deanne Daigle; Kelly A Foley
Journal:  Skin Appendage Disord       Date:  2015-06-26

2.  In Vitro Resistance and Evolution of Resistance to Tavaborole in Trichophyton rubrum.

Authors:  Diletta Mazzantini; Francesco Celandroni; Marco Calvigioni; Antonella Lupetti; Emilia Ghelardi
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  A non-beta-lactam antibiotic inhibitor for enterohemorrhagic Escherichia coli O104:H4.

Authors:  Haoqi Wang; Arul Jayaraman; Rani Menon; Varun Gejji; R Karthikeyan; Sandun Fernando
Journal:  J Mol Med (Berl)       Date:  2019-06-28       Impact factor: 4.599

Review 4.  Synthesis of biologically active boron-containing compounds.

Authors:  Fei Yang; Mingyan Zhu; Jinyi Zhang; Huchen Zhou
Journal:  Medchemcomm       Date:  2017-11-28       Impact factor: 3.597

Review 5.  Recent Advances in the Construction of Fluorinated Organoboron Compounds.

Authors:  Xingxing Ma; Zhijie Kuang; Qiuling Song
Journal:  JACS Au       Date:  2021-12-30

6.  Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases.

Authors:  Nikos Kühl; Johannes Lang; Mila M Leuthold; Christian D Klein
Journal:  Eur J Med Chem       Date:  2022-07-11       Impact factor: 7.088

Review 7.  Molecular targets for antifungals in amino acid and protein biosynthetic pathways.

Authors:  Aleksandra Kuplińska; Kamila Rząd
Journal:  Amino Acids       Date:  2021-06-03       Impact factor: 3.520

Review 8.  Spotlight on tavaborole for the treatment of onychomycosis.

Authors:  Sphoorthi Jinna; Justin Finch
Journal:  Drug Des Devel Ther       Date:  2015-11-20       Impact factor: 4.162

Review 9.  Onychomycosis: A Review.

Authors:  Bianca Maria Piraccini; Aurora Alessandrini
Journal:  J Fungi (Basel)       Date:  2015-03-27

10.  Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei.

Authors:  Pieter C Steketee; Isabel M Vincent; Fiona Achcar; Federica Giordani; Dong-Hyun Kim; Darren J Creek; Yvonne Freund; Robert Jacobs; Kevin Rattigan; David Horn; Mark C Field; Annette MacLeod; Michael P Barrett
Journal:  PLoS Negl Trop Dis       Date:  2018-05-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.